Bremzalerbart clinical trials
Also written REGN5713.
How each study uses bremzalerbart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2021 (1)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Atisnolerbart (3) · Umesolerbart (2)
Studies
Open first, then newest update. How each study uses bremzalerbart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen AllergyTerminatedPhase 3Regeneron PharmaceuticalsNCT07309432Written as REGN5713
- A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen AllergyCompletedPhase 3Regeneron PharmaceuticalsNCT06602739Written as REGN5713
- Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult ParticipantsCompletedPhase 2Regeneron PharmaceuticalsNCT05430919Written as REGN5713
- Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic RhinitisCompletedPhase 3Regeneron PharmaceuticalsNCT04709575Written as REGN5713
Codes
What other systems call bremzalerbart · ClinicalTrials.gg INT016537
- UNII (FDA) F8SN45N8HNBREMZALERBARTOne source FDA
- NCI Thesaurus C190442BremzalerbartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | F8SN45N8HN | BREMZALERBART | One source FDA |
| NCI Thesaurus | C190442 | Bremzalerbart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.